Global Health Limited — Investor Meet, 12-02-2025: Analysts/Institutional Investor Meet/Con. Call Updates

1. Financial Performance: Medanta reported a total income of ₹9,595 million for Q3 FY25, marking a 12% year-over-year growth from ₹8,545 million. The EBITDA stood at ₹2,538 million, up 8% with a margin improvement to 27.5%. Profit after tax increased by 16% to ₹1,429 million, leading to a PAT margin of 14.9%, up from 14.5% in Q3 FY24. Inpatient volumes rose 13% to 44,856, while outpatient volumes grew by 9%. International patient revenue also saw a 14% increase, totalizing ₹541 million in this quarter.

2. Future Outlook and Growth Drivers: Management expressed confidence in sustained growth driven by the expansion of hospitals, including a new 110-bed facility in Ranchi and ongoing construction of a 550-bed hospital in Noida. They aim to add 1,000 beds over the next two years and mentioned the increasing focus on technology and advanced medical procedures as key growth enablers.

3. Order Book and Operational Updates: Management highlighted a steadier performance from both matured and developing hospitals, with revenues for matured hospitals at ₹6,466 million (10% YoY growth) and ₹3,004 million for developing hospitals (9.5% YoY growth). The Lucknow hospital's recent clinical achievements and increased patient engagement are expected to fuel future growth.

4. Analyst Q&A Insights (Detailed):

- Revenue and Profitability: Analysts inquired about the sustainability of increased occupancy rates; management indicated confidence in continued volume growth while keeping an eye on bed capacity expansion.

- Market Position and Competitive Landscape: Questions about competitive threats were addressed, highlighting that increased competition generally elevates care quality rather than undermines it.

- Operational Challenges or Risks: Management acknowledged potential seasonal variations in patient admissions and emphasized their preparedness to adapt.

- Capex and Capital Allocation: Analysts probed into capital expenditures; management clarified plans for significant allocations towards existing and new facilities but refrained from specifying timelines for breakeven.

- Strategic Priorities and Long-Term Vision: Analysts emphasized the importance of maintaining clinical talent and the incorporation of new specialties across facilities.

5. Market or Regulatory Updates: No significant regulatory changes were reported, but management noted ongoing community engagement and responsiveness to local healthcare demands.

6. Strategic Focus Areas: Key themes noted include a commitment to clinical excellence, operational efficiency, and the expansion of service offerings. Management’s optimism indicates a robust strategy focused on enhanced patient care and technological adoption.

7. Investor Insight: Financial performance and strategic initiatives underscore positive growth potential. With key developments in bed capacity and continued emphasis on patient-centric care, the outlook aligns with a ‘buy’ position, recognizing both growth opportunities and the evolving healthcare landscape as beneficial.